BioCentury | Dec 23, 2013
Company News

Retrophin, Transcept, Roumell Asset Management LLC deal

...delivery technology. Retrophin Inc. (OTCQB:RTRX), New York, N.Y. Transcept Pharmaceuticals Inc. (NASDAQ:TSPT), Point Richmond, Calif. Roumell Asset Management LLC...
BioCentury | Sep 30, 2013
Company News

Retrophin, Shin Nippon Biomedical Laboratories, Transcept deal

...approved products. TO-2070 is now listed as Transcept's lead compound. Earlier this month, Transcept shareholders Roumell Asset Management LLC...
BioCentury | Sep 23, 2013
Company News

Retrophin, Transcept deal

...Intermezzo is a low-dose sublingual formulation of zolpidem, a GABA A receptor modulator. Transcept shareholder Roumell Asset Management LLC...
BioCentury | Sep 16, 2013
Company News

Transcept, Purdue Pharma neurology news

..."will be able to announce progress in re-building our development pipeline." The company's largest shareholder, Roumell Asset Management LLC...
Items per page:
1 - 4 of 4
BioCentury | Dec 23, 2013
Company News

Retrophin, Transcept, Roumell Asset Management LLC deal

...delivery technology. Retrophin Inc. (OTCQB:RTRX), New York, N.Y. Transcept Pharmaceuticals Inc. (NASDAQ:TSPT), Point Richmond, Calif. Roumell Asset Management LLC...
BioCentury | Sep 30, 2013
Company News

Retrophin, Shin Nippon Biomedical Laboratories, Transcept deal

...approved products. TO-2070 is now listed as Transcept's lead compound. Earlier this month, Transcept shareholders Roumell Asset Management LLC...
BioCentury | Sep 23, 2013
Company News

Retrophin, Transcept deal

...Intermezzo is a low-dose sublingual formulation of zolpidem, a GABA A receptor modulator. Transcept shareholder Roumell Asset Management LLC...
BioCentury | Sep 16, 2013
Company News

Transcept, Purdue Pharma neurology news

..."will be able to announce progress in re-building our development pipeline." The company's largest shareholder, Roumell Asset Management LLC...
Items per page:
1 - 4 of 4